Optimal care for patients with irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC) includes timely and accurate diagnosis, early initiation of therapies, and effective communication. In this animated on-demand activity, Dr. Brooks Cash shares guideline-based strategies to confirm a diagnosis of IBS-D, IBS-C, or CIC, highlighting critical differential diagnoses to rule out and alarm features that warrant further investigation. This program also features expert insights into the clinical use and mechanism of action of newer/novel treatment options to provide the latest clinical findings on current over-the-counter and prescription treatments for IBS-C, IBS-D, and CIC. Don’t miss this opportunity to learn from Dr. Cash and an actual IBS patient, and download point-of-care tools!
More Information
Chair:
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF
Dan and Lillie Sterling Professor of Medicine
McGovern Medical School
Chief, Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center at Houston
Houston, Texas
Patient Advocate:
Johannah Ruddy, MEd
Learning Objectives:
- Integrate appropriate, validated testing measures to make definitive, timely diagnoses of IBS/CIC
- Treat IBS/CIC in accordance with current evidence and guidelines, recognizing the appropriate use of new and emerging therapeutic agents
- Implement strategies to establish effective communication and help patients with IBS/CIC increase participation in their care
Disclosures
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support from AbbVie Inc.; Ardelyx; QOL Medical, LLC; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau participant with Salix Pharmaceuticals.
Johannah Ruddy, MEd, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Mahana Therapeutics, Inc.
Speaker for AbbVie Inc.; Mahana Therapeutics, Inc.; and Salix/Bausch Health Companies Inc.
Other Financial or Material Support as an independent contractor for Salix/Bausch Health Companies Inc.
Other AGA and PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.
Accreditation Statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose all their financial relationships with ineligible companies held within the past 24 months. The AGA Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.
CME expiration date: Jan. 31, 2023
